Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 6/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11913449 | 1.00 | ALOX5 (0.60) | ALOX5ALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL24599953 | 1.00 | ALOX5 (0.60) | ALOX5ALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL13060191 | 1.00 | ALOX5 (0.60) | ALOX5ALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL12036601 | 1.00 | ALOX5 (0.60) | ALOX5ALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL15259625 | 0.94 | ALOX5 (0.55) | ALOX5ALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL15259577 | 0.94 | ALOX5 (0.55) | ALOX5ALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL15259624 | 0.94 | ALOX5 (0.55) | ALOX5ALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL15259595 | 0.94 | ALOX5 (0.55) | ALOX5ALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL15259592 | 0.94 | ALOX5 (0.55) | ALOX5ALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL16656319 | 0.94 | ALOX5 (0.55) | ALOX5ALDH1A1LMNAHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117441047-A | Treatment agent for synthetic fibers, and method for treating synthetic fibers | 竹本油脂株式会社 | 2024-01-23 | — | — | CN | disclosed |
| US-11826345-B2 | Dosing regimens of PKC activators | Synaptogenix, Inc. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826345-B2 | Dosing regimens of PKC activators | Synaptogenix, Inc. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230000943-A1 | METHOD OF INDUCING SYNAPTOGENESIS BY ADMINISTERING ANGIOTENSIN AND ANALOGUES THEREOF | Synaptogenix, Inc. (US) | 2023-01-05 | — | — | US | disclosed |
| WO-2022219889-A1 | TREATMENT AGENT FOR SYNTHETIC FIBERS, SYNTHETIC FIBERS, AND TREATMENT METHOD FOR SYNTHETIC FIBERS | 竹本油脂株式会社 | 2022-10-20 | — | — | WO | disclosed |
| US-20220265857-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2022-08-25 | — | — | US | disclosed |
| EP-3386484-B1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11285222-B2 | Compositions and methods for delivery of agents | MODERNATX, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210023048-A1 | DOSING REGIMENS OF PKC ACTIVATORS | COGNITIVE RESEARCH ENTERPRISES, INC. (US) | 2021-01-28 | — | — | US | disclosed |
| US-20200206362-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | Moderna TX, Inc. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| WO-2017099823-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017099823-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
| US-20140315990-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | COGNITIVE RESEARCH ENTERPRISES, INC. | 2014-10-23 | — | — | US | disclosed |
| US-20140315990-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | COGNITIVE RESEARCH ENTERPRISES, INC. | 2014-10-23 | — | — | US | disclosed |
| US-20140235496-A1 | STIMULUS-ELICITED GENOMIC PROFILE MARKERS OF A NEURODEGENERATIVE CONDITION | BLANCHETTE ROCKEFELLER NEUROSCIENCES DRIVE (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235496-A1 | STIMULUS-ELICITED GENOMIC PROFILE MARKERS OF A NEURODEGENERATIVE CONDITION | BLANCHETTE ROCKEFELLER NEUROSCIENCES DRIVE (US) | 2014-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206362-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | ALOX5 3206/4885ALDH1A1 3952/4885LMNA 248/4885 |
| US-11285222-B2 | Compositions and methods for delivery of agents | HDLBP, APOB, TSG101 | ALOX5 3206/4885ALDH1A1 3952/4885LMNA 248/4885 |
| US-20230000943-A1 | METHOD OF INDUCING SYNAPTOGENESIS BY ADMINISTERING ANGIOTENSIN AND ANALOGUES THEREOF | GAP43, SNAP29, SYNGR2 | ALOX5 443/4885ALDH1A1 4331/4885LMNA 2577/4885 |
| US-20210023048-A1 | DOSING REGIMENS OF PKC ACTIVATORS | PRKCA, PRKCH, PRKCQ | ALOX5 2400/4885ALDH1A1 4374/4885LMNA 2436/4885 |
| US-20220265857-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | ALOX5 3206/4885ALDH1A1 3952/4885LMNA 248/4885 |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | ALOX5 3206/4885ALDH1A1 3952/4885LMNA 248/4885 |
| US-20140315990-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | PRKCH, PRKCB, PRKCA | ALOX5 3192/4885ALDH1A1 4622/4885LMNA 1261/4885 |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | ALOX5 3206/4885ALDH1A1 3952/4885LMNA 248/4885 |
| US-11826345-B2 | Dosing regimens of PKC activators | PRKCA, PRKCH, PRKCQ | ALOX5 2400/4885ALDH1A1 4374/4885LMNA 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.